Edoxaban Versus Warfarin for the Treatment of Symptomatic Venous Thromboembolism - Hokusai-VTE


Recent studies have demonstrated the potential to dramatically change the management strategy for acute venous thromboembolism (VTE). Agents such as rivaroxaban and apixaban have shown similar efficacy as warfarin with reduction in bleeding in these patients. The current trial sought to study the safety and efficacy of edoxaban, another oral direct factor Xa inhibitor, as compared with warfarin for the treatment of acute VTE.